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Purpose: We investigated the efficacy of ketoconazole and estramustine before chemo-
therapy for treating patients with progressive castration-resistant prostate cancer 
(CRPC) after anti-androgen withdrawal syndrome.
Materials and Methods: Eighty-four patients who were diagnosed with CRPC and were 
treated between 2005 and 2009 were included. Thirty-nine patients were treated with 
600 mg of ketoconazole and 10 mg of prednisolone per day (group I), and 45 patients 
were treated with 560 mg of estramustine per day (group II). The prostate-specific anti-
gen (PSA) response, progression-free survival, and side effects were compared. 
Results: The median age of the patients, PSA level, and follow-up period were 72 years, 
48.5 ng/ml, and 4 months (range, 1 to 29 months), respectively. The overall PSA re-
sponse rate was 35.7%, and the PSA response rates were 33.3% for group I and 37.8% 
for group II (p=0.672). The median progression-free survival times were 8 months (95% 
confidence interval [CI] 5.9-10.1) overall, 5 months (95% CI 1.6-8.3) in group I, and 8 
months (95% CI 5.9-10.0) in group II (p=0.282). The most common complications in 
groups I and II were nausea and vomiting (51.3%) and anemia (77.8%), respectively. 
Nausea and vomiting and hepatotoxicity were observed more often in group I, and gyne-
comastia, neutropenia, and anemia were observed more often in group II. The toxicities 
of each adverse effect were ≤grade 2. 
Conclusions: With a resultant PSA decline and mild adverse effects, both ketoconazole 
and estramustine are worth consideration as treatment options for progressive CRPC 
patients after primary hormonal therapy.
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INTRODUCTION 
For patients with progressive castration-resistant pros-
tate cancer (CRPC) despite castration serum testosterone 
levels following initial androgen-deprivation therapy 
(ADT) for advanced prostate cancer, the therapeutic op-
tions before systemic chemotherapy, such as docetaxel, are 
anti-androgen withdrawal, replacement of anti-andro-
gens, and secondary hormonal therapy [1].
After anti-androgen withdrawal syndrome in patients 
with CRPC, drugs for secondary hormonal manipulations 
include aminoglutethimide, ketoconazole, corticosteroids, 
and estrogenic compounds. Ketoconazole, a broad-spec-
trum anti-fungal agent, inhibits steroidogenesis in the 
testes and adrenal glands, and estramustine exerts not on-
ly non-hormonal cytotoxic effects, but also hormonal estro-
genic effects. Thus, ketoconazole and estramustine serve 
as excellent treatment modalities in patients with CRPC 
[2].
Although several studies have been conducted regarding 
the therapeutic effects of ketoconazole and estramustine, 
comparisons of these treatments are limited in the 
literature. Thus, we investigated the efficacy, pro-
gression-free survival, and adverse effects of ketoconazole Korean J Urol 2011;52:746-751
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and estramustine as a secondary hormonal therapy follow-
ing anti-androgen withdrawal syndrome in patients with 
CRPC. 
MATERIALS AND METHODS
This study was conducted in accordance with the 
Declaration of Helsinki.
1. Study population
The medical records of 84 patients with CRPC who were 
treated with ketoconazole and estramustine as a secon-
dary hormonal therapy between 2005 and 2009 were retro-
spectively reviewed. CRPC was defined as biochemical or 
radiologic progression after initial ADT, despite castration 
levels of serum testosterone (＜50 ng/dl or 1.7 nmol/l). We 
considered biochemical progression as 3 consecutive in-
creases in the PSA level at least 1 week apart, resulting in 
2 increases over the nadir by 50%. Either anti-androgen 
withdrawal or one secondary hormonal manipulation 
should have been done to fulfill the criteria for CRPC. 
Radiologic progression included the appearance of ≥2 new 
lesions on bone scanning or soft tissue (nodal and visceral) 
lesions with use of the Response Evaluation Criteria in 
Solid Tumors and with lymph nodes ≥2 cm in diameter [3].
2. Data collection
Enrolled subjects were divided into 2 groups according to 
the drug therapy (group I: n=39, ketoconazole+predniso-
lone [PD] vs. group II: n=45, estramustine monotherapy). 
In group I, patients were administered ketoconazole (200 
mg orally 3 times daily), unlike the majority of previous 
high-dose ketoconazole (400 mg) studies, with PD (5 mg 
twice daily) routinely to counteract the potential adrenal 
insufficiency induced by ketoconazole. Estramustine was 
administered orally twice a day for a total dose of 560 
mg/day (group II). Patient characteristics, including age 
and prostate-specific antigen (PSA) level, both at the time 
of diagnosis and at the time the second drug was started; 
the Gleason score; clinical stage; prior treatment; PSA re-
sponse; progression-free survival time; and adverse effects 
were collected for analyses. 
We classified the PSA response into the following 4 cate-
gories: complete response was a PSA level below the normal 
baseline (4 ng/dl) for ≥4 weeks, partial response was ＞a 
50% decrease from baseline, stable disease was a ＜50% de-
cline and a 20% increase from baseline, and progressive 
disease was a ≥20% increase from baseline. Stable and 
progressive disease were considered as the nonresponse 
group [3].
Toxicity was graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events v4.0.
3. Statistical analysis
Student’s t-test, chi-square test, and Fisher's exact test 
were used to compare the two groups with respect to re-
sponse rates and adverse effects. Progression-free survival 
times were calculated and compared by using the 
Kaplan-Meier method and the log-rank test. A p-value 
＜0.05 was considered statistically significant.
RESULTS
1. Baseline characteristics
The baseline median age of the entire study group of 84 pa-
tients was 72 years (range, 50 to 90 years), the median PSA 
level was 48.5 ng/ml (range, 1 to 3,869 ng/ml), and the me-
dian follow-up period was 4 months (range, 1 to 29 months). 
The Gleason score was ≥8 in 53 patients (63.1%), the clin-
ical stage was ≥T3 in 53 patients (63.1%), and bone meta-
stasis was present in 52 patients (61.9%). Sixty-nine pa-
tients (82.1%) previously received LHRH agonist therapy, 
and 15 patients (17.9%) underwent orchiectomies. The age, 
PSA level, Gleason score, clinical stage, and prior treat-
ment at the beginning of secondary hormonal therapy were 
not statistically different (Table 1).
2. Prostate-specific antigen response rate and progre-
ssion-free survival
Of the entire study group, 30 patients (35.7%) had a PSA 
response (complete or partial response), and 54 patients 
(64.3%) had no response (stable or progressive disease). 
The PSA response rate was higher in the estramustine 
group than in the ketoconazole group (37.8% vs. 33.3%); 
however, there was no statistical difference between the 
groups (p=0.672) (Table 2). Also, the PSA response rates 
according to Gleason score (p=0.371) and the clinical stage 
(p=0.839) showed no statistical difference (Tables 3, 4).
The median progression-free survival was 8 months 
(95% confidence interval [CI] 5.9-10.1) overall; the median 
progression-free survival was 5 months (95% CI 1.6-8.3) in 
the ketoconazole group and 8 months (95% CI 5.9-10.0) in 
the estramustine group. The progression-free survival was 
not statistically different between the groups (p=0.282) 
(Fig. 1).
3. Adverse effect of each drug
The most common side effect in the ketoconazole group was 
nausea and vomiting (51.3%), whereas the most common 
side effect in the estramustine group was anemia (77.8%). 
The frequency of anorexia (15 vs. 11, p=0.166) and facial 
edema (11 vs. 8, p=0.255) was similar in both groups, but 
nausea and vomiting (20 vs. 11, p=0.011) and hepatotox-
icity (9 vs. 2, p=0.012) were more common in the ketocona-
zole group, and gynecomastia (3 vs. 15, p=0.004), neu-
tropenia (0 vs. 9, p=0.003), and anemia (0 vs. 35, p=0.001) 
were more common in the estramustine group. All docu-
mented side effects were ≤grade 2 (Table 5).
DISCUSSION
In this study, there were no significant differences in PSA 
responses or progression-free survival between the ketoco-Korean J Urol 2011;52:746-751
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TABLE 1. Patient characteristics
Median (range) or n (%)
Total (n=84) Group I (n=39) Group II (n=45) p-value
Age at diagnosis (yr)
PSA at diagnosis (ng/ml)
Age at start second drug (yr)
PSA at start second drug (ng/ml)
Gleason score
    4-6
    7
    8-10
Clinical stage
    T1
    T2
    T3-T4
    Unknown
Clinical N stage
    N0
    Nx
    Unknown
Clinical M stage
    M0
    M1
    Mx
    Unknown
Prior treatments
    LHRH agonist
    Orchiectomy
69.5 (49-87)
       100.3 (5.2-3,080.4)
72.0 (50-90)
   48.5 (1-3,869)
6 (7.1)
25 (29.8)
53 (63.1)
0 (0.0)
22 (26.2)
53 (63.1)
   9 (10.7)
36 (42.9)
40 (47.6)
8 (9.5)
26 (31.0)
52 (61.9)
1 (1.2)
5 (6.0)
69 (82.1)
15 (17.9)
71.0 (50-87)
       100.0 (6.0-3,080.4)
72.0 (51-89)
   60.4 (1-3,869)
  4 (10.3)
10 (25.6)
25 (64.1)
0 (0.0)
13 (33.3)
22 (56.4)
  4 (10.3)
18 (46.2)
17 (43.6)
  4 (10.3)
12 (30.8)
24 (61.5)
0 (0.0)
3 (7.7)
31 (79.5)
  8 (20.5)
69.0 (49-84)
        106.6 (5.26-1578.0)
71.0 (50-90)
44.5 (3-789)
2 (4.4)
15 (33.3)
28 (62.2)
0 (0.0)
   9 (20.0)
31 (68.9)
   5 (11.1)
18 (40.0)
23 (51.1)
4 (8.9)
14 (31.1)
28 (62.2)
1 (2.2)
2 (4.4)
38 (84.4)
   7 (15.6)
0.866
a
0.322
a
0.512
a
0.390
a
0.533
b
0.409
b
0.770
b
0.933
b
0.554
c
Values are presented as median (range) or n (%), Group I: ketoconazole+prednisolone, Group II: estramustine, 
a: Student’s t-test, 
b: 
Fisher's exact test, 
c: Chi-square test
TABLE 2. PSA responses according to treatment
PSA response
No. of patients (%)
Total Group I Group II p-value
Response
    Complete response
a
    Partial response
b
Nonresponse
    Stable disease
c
    Progressive disease
d
30 (35.7)
  9 (10.7)
21 (25.0)
54 (64.3)
36 (42.9)
18 (21.4)
13 (33.3)
  4 (10.3)
  9 (23.1)
26 (66.7)
18 (46.2)
  8 (20.5)
17 (37.8)
  5 (11.1)
12 (26.7)
28 (62.2)
18 (40.0)
10 (22.2)
0.672
e
Total 84 (100) 39 (100) 45 (100)
Values are presented as number (%), Group I: ketoconazole+pre-
dnisolone, Group II: estramustine, PSA: prostate-specific anti-
gen, 
a: PSA level below the normal baseline (4 ng/dl) for ≥4 weeks 
or more, 
b: ≥50% decrease from baseline, 
c: Between a ＜50% de-
cline and a 20% increase from baseline, 
d: ≥20% increase from 
baseline, 
e: Chi-square test
TABLE 3. PSA responses according to Gleason score
PSA response
Gleason score (%)
4-6 7 8-10 p-value
Response
    Complete response
a
    Partial response
b
Nonresponse
    Stable disease
c
    Progressive disease
d
3 (50.0)
2 (33.3)
1 (16.7)
3 (50.0)
2 (33.3)
1 (16.7)
11 (44.0)
  3 (12.0)
  8 (32.0)
14 (56.0)
  9 (36.0)
  5 (20.0)
16 (30.2)
4 (7.6)
12 (22.6)
37 (69.8)
25 (47.2)
12 (22.6)
0.371
e
Total 6 (100) 25 (100) 53 (100)
Values are presented as number (%), PSA: prostate-specific anti-
gen, 
a: PSA level below the normal baseline (4 ng/dl) for ≥4 weeks 
or more, 
b: ≥50% decrease from baseline, 
c: Between a ＜50% de-
cline and a 20% increase from baseline, 
d: ≥20% increase from 
baseline, 
e: Chi-square test
nazole and estramustine groups. The results were similar 
to previous studies for each drug [4-9].
Recently, the term CRPC has been used in comparison 
with hormone-refractory prostate cancer (HRPC), which 
refers to prostate cancer that has progressed or recurred 
after the initial hormonal ablation therapy. Distinguish-
ing CRPC and HRPC is very important because HRPC is 
resistant to all hormone therapies, whereas CRPC is re-
sponsive to secondary hormone therapies such as anti-an-
drogen withdrawal, estrogens, and corticosteroids.
Ketoconazole was originally a broad-spectrum azole an-
ti-fungal agent that inhibits cytochrome p450 enzymes and 
thus inhibits androgen synthesis from steroid precursors Korean J Urol 2011;52:746-751
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TABLE 4. PSA responses according to clinical stage
PSA response
Clinical T stage (%)
T1 T2 T3-4 Unknown p-value
Response
    Complete response
a
    Partial response
b
Nonresponse
    Stable disease
c
    Progressive disease
d
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
  9 (40.9)
  4 (18.2)
  5 (22.7)
13 (59.1)
10 (45.5)
  3 (13.6)
18 (34.0)
5 (9.5)
13 (24.5)
35 (66.0)
21 (39.6)
14 (26.4)
3 (33.3)
0 (0.0)
3 (33.3)
6 (66.7)
5 (55.6)
1 (11.1)
0.839
e
Total 0 (0.0) 22 (100) 53 (100) 9 (100)
Values are presented as number (%), PSA: prostate-specific antigen, 
a: PSA level below the normal baseline (4 ng/dl) for ≥4 weeks 
or more, 
b: ≥50% decrease from baseline, 
c: Between a ＜50% decline and a 20% increase from baseline, 
d: ≥20% increase from baseline, 
e: Chi-square test
FIG. 1. Progression-free survival curves according to treatment 
groups were not statistically different by the log-rank test. The 
median progression-free survival times were 8 months (95% 
confidence interval [CI] 5.9-10.1) overall, 5 months (95% CI 
1.6-8.3) in group I and 8 months (95% CI 5.9-10.0) in group II 
(p=0.282). Group I: ketoconazole+prednisolone, Group II: 
estramustine.
TABLE 5. Adverse effects according to treatment
Adverse effects
No. of patients (%)
Group I 
(n=39)
Group II 
(n=45)
p-value
Nausea/vomiting
Anorexia
Facial edema
Gynecomastia
Liver toxicity
Neutropenia
Anemia
20 (51.3)
15 (38.5)
11 (28.2)
3 (7.7)
  9 (23.1)
0 (0.0)
0 (0.0)
11 (24.4)
11 (24.4)
  8 (17.8)
15 (33.3)
2 (4.4)
  9 (20.0)
35 (77.8)
0.011
a
0.166
a
0.255
a
0.004
a
0.012
a
0.003
a
0.001
a
Values are presented as number (%), Group I: ketoconazole+pre-
dnisolone, Group II: estramustine, 
a: Chi-square test
leading to loss of adrenal steroid synthesis and testoster-
one synthesis by Leydig cells. Ketoconazole is commonly 
used with hydrocortisone because of its adrenal-sup-
pressive effect [10]. Choi et al analyzed 11 HRPC cases in 
which ketoconazole (200 mg 3 times daily) and PD (5 mg 
2 or 3 times daily) combination therapy was used and 10 
cases in which PD monotherapy was used [4]. In the ketoco-
nazole-PD combination therapy group, the mean PSA re-
duction was 23%, and the PSA decreased ＞50% in 27% of 
the patients. The mean response time was 5.2 months, 
which was similar to the PD monotherapy group. Wilkin-
son and Chodak analyzed 38 patients in whom prostate 
cancer progressed despite combined androgen blockade 
and then used intermediate-dose ketoconazole (300 mg 3 
times daily) and replacement hydrocortisone [5]. Of the 38 
patients, 21 (55.3%) had a PSA reduction ＞50%. The me-
dian time-to-progression and the median survival were 5 
months and 12 months, respectively. In a prospective, 
randomized phase III trial, androgen-independent pros-
tate cancer patients were targeted, and the therapeutic ef-
fect of anti-androgen withdrawal (AAWD) alone (n=132) 
was compared with that of simultaneous AAWD and keto-
conazole (400 mg 3 times daily) plus hydrocortisone ther-
apy (n=128) [6]. A PSA decline of ＞50% was observed in 
11% of the patients undergoing AAWD. The median 
time-to-PSA progression was 5.9 months. A PSA decrease 
of ＞50% was observed in 27% of patients treated with con-
current AAWD and ketoconazole and in 32% of patients 
treated with ketoconazole after AAWD. The median 
time-to-PSA progression was 5.9 months in patients treat-
ed with AAWD alone and 8.6 months in patients treated 
with simultaneous AAWD and ketoconazole. According to 
Scholz et al, in 78 patients with high-dose ketoconazole 
(400 mg every 8 hours) and hydrocortisone, the median 
time-to-PSA progression and median survival time were 
6.7 and 42.4 months, respectively [7]. A total of 34 (44 %) 
men had a decrease in PSA ＞75%. Their data indicated 
that a PSA decrease ＞75% predicted better survival than 
that in men with a ＜75% decrease. 
Estramustine, a combination of estradiol phosphate and 
nornitrogen mustard, shows cytotoxicity by suppressing 
microtubules. Estramustine has toxicity similar to estro-Korean J Urol 2011;52:746-751
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gen because the metabolite, estrogen, acts as a hormone 
that lowers the blood level of testosterone, leading to sup-
pression of testosterone-sensitive tumor growth [11,12]. 
Han et al compared HRPC patients treated with estramus-
tine monotherapy (n=11), estramustine and etoposide 
(n=12), or dexamethasone (n=10) combination therapy. 
The total PSA response rate was 48.5%. In the mono-
therapy group, etoposide combination therapy group, and 
dexamethasone combination therapy group, the PSA re-
sponse rates were 36.4%, 41.7%, and 70.0%, respectively 
[8]. The overall median time-to-progression was 5 months, 
whereas in the monotherapy group, etoposide combination 
therapy group, and dexamethasone combination therapy 
group, it was 5 months, 5.5 months, and 5 months, 
respectively. The overall 1 and 2 year survival rates were 
63.6% and 27.6%, respectively. Hirano et al conducted a 
prospective study focusing on the efficacy of estramustine 
phosphate monotherapy after ADT in 29 HRPC patients; 
in 7 (24%) patients, the PSA decreased ＞50%, the median 
duration of PSA response was 8.0 months, and the can-
cer-specific survival rates at 1 and 2 years were 72% and 
53%, respectively [9]. The cancer-specific survival rate at 
2 years was 83% in the PSA responders and 44% in the 
nonresponders. 
In this study, 33.3% of the patients in the ketoconazole 
group had a PSA response, and the median progre-
ssion-free survival was 5 months. In the estramustine 
group, 37.8% of the patients had a PSA response, and the 
median progression-free survival was 8 months, indicating 
that there was no statistically significant difference be-
tween the two groups. Furthermore, the PSA response and 
progression-free survival were similar to those reported in 
previous studies [4-9]. Because the second drugs were 
started at the time the disease had already progressed to 
CRPC, it was predictable that there would be no significant 
differences in the PSA response rates according to Gleason 
score and the clinical stage categorized at the time of pros-
tate cancer diagnosis.
Small et al reported that 21% of ketoconazole-treated pa-
tients experienced grade 3 and 4 toxicities, including neu-
rologic toxicity (4%), malaise or fatigue (3%), and hepatic 
toxicity [6]. According to Wilkinson et al, ketoconazole-re-
lated toxicity occurred in 31.6% of patients, consisting of 
nausea (13.2%), fatigue (10.6%), diarrhea (2.6%), visual 
disturbance (2.6%), and abnormal liver function tests 
(2.6%), and 6 (15.8%) patients discontinued ketoconazole 
treatment owing to intolerable side effects [5]. Estramu-
stine commonly increases the risk of gastrointestinal prob-
lems, gynecomastia, lower extremity edema, and car-
diovascular death. Estramustine can also increase the risk 
of thromboembolism, and in the study by Han et al, throm-
boembolism occurred in 6.1% of patients treated with es-
tramustine [8]. Hirano et al reported that 15% of patients 
discontinued estramustine treatment due to severe gastro-
intestinal symptoms [9]. In this study, the common side ef-
fects reported in other studies were present, but the toler-
ance was relatively good, with ≤grade 2 side effects, and 
no patients discontinued the medication because of serious 
complications.
This study was not without limitations. First, besides the 
retrospective nature of the study and the small number of 
enrolled patients, we did not analyze disease-specific 
survival. Second, estramustine was a cytotoxic agent rath-
er than a hormonal agent, but we used estramustine for its 
estrogenic effect. Third, we did not continue ADT because 
of Korean health insurance issues. 
CONCLUSIONS
Both ketoconazole and estramustine showed a PSA decline 
in CRPC patients before systemic chemotherapy and had 
mild adverse effects. Thus, either ketoconazole or estra-
mustine can be considered as a treatment option for pro-
gressed CRPC patients after primary hormonal therapy. 
Ketoconazole and estramustine should be used appropri-
ately according to the general conditions of patients and 
with consideration of the potential side effects of the 
medications. Also, we suggest that comparing ketocona-
zole following estramustine and estramustine following 
ketoconazole would be beneficial to determine optimal sec-
ondary hormone therapy in CRPC patients before docetax-
el chemotherapy.
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